Findings

What do systematic reviews say?

5 questions · 7 findings · 2 reviews · Vascular

No studies found 3 · 42.9%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 14.3%Moderate 3 · 42.9%High 0 · 0%

1‐year overall mortality · ambulatory cancer patients receiving chemotherapy

Unfractionated heparin showed no clear difference in 1‐year overall mortality compared with no thromboprophylaxis (moderate certainty).

1 finding from 1 review

1‐year overall mortality · ambulatory cancer patients receiving chemotherapy

Low‐molecular‐weight heparin showed no clear difference in 1‐year overall mortality compared with no thromboprophylaxis (low certainty).

1 finding from 1 review

1‐year overall mortality · ambulatory cancer patients receiving chemotherapy

The review found no eligible studies for this question.

3 findings from 1 review

Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found
Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found
Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

1‐year overall mortality · ambulatory cancer patients receiving chemotherapy

Ultra‐low‐molecular‐weight heparin showed no clear difference in 1‐year overall mortality compared with placebo (moderate certainty).

1 finding from 1 review

Overall mortality (end of · patients with venous thromboembolism.

LMWH showed no clear difference in overall mortality (end of compared with UFH (moderate certainty).

1 finding from 1 review